The abstract is read at the publisher; the summary is JClub's.
Left atrial appendage closure (LAAC) RCTs in atrial fibrillation are heterogeneous, so pooled estimates may not apply to a single patient group or decision.
- Why it matters: Clinicians need guidance on whether LAAC can replace anticoagulation, but trial differences in eligibility, comparators, endpoints, and bleeding definitions limit what any summary effect can mean.
- What they did: This JACC Evidence Review treats major LAAC RCTs (OPTION, CLOSURE-AF, CHAMPION-AF) as distinct experiments, highlighting differences in phenotype, device generation, antithrombotic regimens, and follow-up, and critiques meta-analytic pooling when trials diverge materially.
- The result: For most anticoagulation-eligible patients, anticoagulation remains preferred first-line, while LAAC is reasonable only when long-term anticoagulation is unsafe or unsustainable, with careful attention to procedural risk and feasibility.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.